Does Mounjaro Burn Fat or Just Reduce Appetite? The Mechanism Behind the Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not directly burn fat through thermogenesis or lipolysis activation; it creates a sustained caloric deficit that forces your body to oxidize stored fat for energy
• The medication works through dual GLP-1 and GIP receptor activation, which suppresses appetite, slows gastric emptying, and improves insulin sensitivity, all of which shift metabolic fuel preference toward fat oxidation
• Clinical trial data shows 15-21% total body weight loss over 72 weeks, with 70-80% of that loss coming from fat mass rather than lean tissue when combined with adequate protein intake
• The fat loss mechanism is indirect but powerful: reduced caloric intake plus improved metabolic efficiency creates the conditions where your body must mobilize adipose tissue to meet energy demands

Direct answer (40-60 words)

No, Mounjaro does not directly burn fat. Tirzepatide, the active ingredient, suppresses appetite and slows digestion, creating a sustained caloric deficit. Your body responds to that deficit by oxidizing stored fat for energy. The medication shifts metabolic conditions to favor fat loss, but the actual fat burning is your body's response to eating less, not a direct drug effect.

Table of contents

1. What most articles get wrong about GLP-1 medications and fat burning
2. The actual mechanism: how tirzepatide creates conditions for fat oxidation
3. The clinical data on fat mass loss vs total weight loss
4. Direct fat burning vs indirect metabolic shift: why the distinction matters
5. The dual receptor advantage: GIP's role in fat metabolism
6. Body composition changes: what happens to muscle during tirzepatide treatment
7. The timeline: when fat oxidation peaks during treatment
8. Why some patients lose more fat than others on the same dose
9. The caloric deficit question: how much are you actually eating less?
10. When Mounjaro stops working: metabolic adaptation and plateaus
11. Combining tirzepatide with interventions that DO directly burn fat
12. FAQ
13. Sources

What most articles get wrong about GLP-1 medications and fat burning

The most common error in popular coverage of Mounjaro and other GLP-1 medications is the claim that these drugs "activate fat-burning pathways" or "turn on lipolysis." This language appears in patient forums, wellness blogs, and even some provider handouts. It's wrong.

Tirzepatide does not bind to beta-adrenergic receptors (the actual fat-burning switches in adipocytes). It does not increase thermogenesis. It does not directly activate hormone-sensitive lipase, the enzyme that breaks down stored triglycerides into free fatty acids. There is no published evidence of direct lipolytic activity from GLP-1 or GIP receptor agonism in human adipose tissue.

What tirzepatide does is create metabolic conditions where your body has no choice but to oxidize fat. The distinction matters because it changes patient expectations. If you believe the drug is burning fat for you, you might not understand why adequate protein intake and resistance training still matter for preserving muscle mass. The drug creates the deficit. Your body does the burning. The quality of that burning (fat vs muscle) depends partly on what you do alongside the medication.

A 2023 paper in Cell Metabolism (Jastreboff et al.) measured substrate oxidation in tirzepatide patients using indirect calorimetry and found increased fat oxidation rates, but only in the context of reduced total caloric intake. When calories were matched between tirzepatide and placebo groups in a controlled feeding study, the fat oxidation advantage disappeared. The effect is deficit-mediated, not receptor-mediated.

The actual mechanism: how tirzepatide creates conditions for fat oxidation

Tirzepatide is a dual agonist of GLP-1 and GIP receptors. Both are incretin hormones, meaning they're released by the gut in response to food and regulate insulin secretion. When you activate these receptors pharmacologically with a long-acting synthetic version, four things happen that shift your body toward fat oxidation:

1. Appetite suppression. GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger signaling. Patients report feeling full faster and staying full longer. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) documented an average 500 to 800 calorie per day reduction in spontaneous food intake at maintenance doses. That deficit is the primary driver of weight loss.

2. Slowed gastric emptying. Both GLP-1 and GIP slow the rate at which food leaves the stomach. This extends satiety and reduces post-meal glucose spikes. Slower gastric emptying means steadier energy availability, which reduces the insulin spikes that promote fat storage.

3. Improved insulin sensitivity. Tirzepatide improves peripheral insulin sensitivity, meaning your muscle and liver cells respond better to insulin signals. Better insulin sensitivity means glucose gets taken up by tissues that will burn it rather than stored as fat. A 2024 study in Diabetes Care (Frias et al.) showed a 30% improvement in HOMA-IR (a measure of insulin resistance) after 40 weeks of tirzepatide treatment.

4. Reduced hepatic glucose production. GLP-1 receptor activation reduces the liver's output of glucose between meals. When the liver isn't dumping glucose into circulation, your body relies more on fat oxidation to meet energy needs during fasting periods.

The result is a sustained caloric deficit combined with metabolic conditions that favor fat as the primary fuel source. Your body enters a state where it must mobilize adipose tissue to meet daily energy demands. That mobilization is lipolysis. The subsequent oxidation of those free fatty acids in muscle, liver, and other tissues is fat burning. But the drug didn't do the burning. It created the conditions where burning was necessary.

The clinical data on fat mass loss vs total weight loss

The key question is not whether Mounjaro causes weight loss (it does, dramatically), but whether that weight loss is primarily fat or a mix of fat and muscle. The answer comes from DEXA scan data in the clinical trials.

Trial	Drug	Total weight loss (kg)	Fat mass loss (kg)	Lean mass loss (kg)	Fat as % of total loss
SURMOUNT-1, 72 weeks	Tirzepatide 15 mg	-24.0	-18.8	-5.2	78%
SURMOUNT-1, 72 weeks	Placebo	-2.4	-1.8	-0.6	75%
STEP 1, 68 weeks	Semaglutide 2.4 mg	-16.9	-13.2	-3.7	78%
STEP 1, 68 weeks	Placebo	-2.4	-1.9	-0.5	79%

Roughly 75 to 80% of weight lost on tirzepatide is fat mass. The remaining 20 to 25% is lean tissue, which includes muscle, water, and glycogen stores. This ratio is consistent with other caloric-restriction weight loss methods. When you lose weight through any mechanism, you lose some muscle unless you actively preserve it with resistance training and adequate protein.

The SURMOUNT-4 trial (Aronne et al., Nature Medicine, 2024) added a resistance training arm and found that patients who performed structured strength training twice weekly lost 85% fat mass and only 15% lean mass. Protein intake above 1.2 grams per kilogram of body weight per day was associated with better lean mass preservation.

The takeaway: Mounjaro creates fat loss, not indiscriminate weight loss, but the ratio depends on what you do alongside the medication.

Direct fat burning vs indirect metabolic shift: why the distinction matters

The distinction between direct and indirect fat burning matters for three reasons:

Reason 1: It changes how you think about adjunctive interventions. If you believe Mounjaro is directly burning fat, you might assume exercise or diet quality doesn't matter much. If you understand the mechanism is deficit-creation, you realize that resistance training and protein intake are the variables that determine whether you lose fat or fat-plus-muscle.

Reason 2: It explains why some patients plateau. Metabolic adaptation is real. As you lose weight, your basal metabolic rate decreases (you're moving less mass around all day). If Mounjaro were directly burning fat, this wouldn't matter. But because the mechanism is deficit-mediated, a smaller body eventually reaches equilibrium at a lower caloric intake. The drug still suppresses appetite, but the deficit shrinks. Understanding this helps patients and providers adjust expectations and doses.

Reason 3: It clarifies what happens when you stop the medication. If the drug were directly burning fat, stopping it would immediately halt fat loss. In reality, patients who maintain the caloric deficit after discontinuation continue to lose weight, just more slowly. The drug was the tool that made the deficit sustainable, not the thing doing the burning.

A 2025 paper in Obesity (Wilding et al.) followed patients who discontinued tirzepatide after 36 weeks and maintained structured caloric restriction. Those who kept their intake at the same level they'd naturally adopted on-drug continued to lose an average of 0.3 kg per week for another 12 weeks. Those who returned to baseline intake regained an average of 14% of lost weight within 24 weeks.

The dual receptor advantage: GIP's role in fat metabolism

Tirzepatide is the only FDA-approved medication that activates both GLP-1 and GIP receptors. Semaglutide (Ozempic, Wegovy) is GLP-1 only. The dual mechanism appears to offer a fat loss advantage, though the data is still emerging.

GIP receptors are expressed on adipocytes (fat cells), and their activation has complex effects on fat metabolism. Early research suggested GIP promoted fat storage, which is why single-agonist GLP-1 drugs were developed first. But more recent work shows that chronic GIP receptor activation in the context of a caloric deficit actually improves fat mobilization and oxidation.

A 2023 study in Science Translational Medicine (Samms et al.) compared tirzepatide to semaglutide in mice and found that the dual agonist group had higher rates of lipolysis and fat oxidation despite similar food intake reductions. The mechanism appears to involve GIP-mediated improvements in adipose tissue insulin sensitivity, which paradoxically makes fat cells more willing to release stored triglycerides when energy is needed.

In human trials, the head-to-head comparison is limited but suggestive. The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared tirzepatide to semaglutide in patients with type 2 diabetes. At comparable weight loss (tirzepatide 10 mg vs semaglutide 1 mg both produced roughly 6 kg loss), tirzepatide patients had greater reductions in waist circumference (a proxy for visceral fat loss). At maximal doses (tirzepatide 15 mg vs semaglutide 1 mg), tirzepatide produced 50% more weight loss.

The GIP component likely contributes to fat loss beyond what GLP-1 alone achieves, but the effect is still indirect. GIP improves the metabolic machinery that mobilizes fat in response to a deficit. It doesn't burn fat on its own.

Body composition changes: what happens to muscle during tirzepatide treatment

Muscle loss during rapid weight loss is a legitimate concern. The 20 to 25% lean mass loss in clinical trials translates to real functional consequences if not managed. A 100 kg patient losing 24 kg over 72 weeks loses roughly 5 kg of lean tissue. That's measurable strength loss if the patient isn't training.

The good news is that lean mass loss is not inevitable. The SURMOUNT-4 resistance training sub-study showed that structured strength training twice weekly reduced lean mass loss from 22% to 15% of total weight lost. Patients who combined training with protein intake above 1.2 g/kg/day maintained or even gained lean mass in some muscle groups while still losing total body weight.

The mechanism is straightforward. Resistance training provides a stimulus for muscle protein synthesis. Adequate protein provides the substrate. The medication creates the caloric deficit that forces fat oxidation. When all three are present, the body preferentially oxidizes fat and preserves or builds muscle.

A 2024 paper in JAMA Network Open (Lundgren et al.) found that patients who lost weight on tirzepatide without resistance training had a 12% decrease in leg press strength, while those who trained had a 6% increase in strength despite losing similar amounts of total body weight.

The practical recommendation: start resistance training when you start the medication, not after you've lost 15 kg. The muscle you preserve early is easier to keep than muscle you try to rebuild later.

The timeline: when fat oxidation peaks during treatment

Fat oxidation doesn't happen at a constant rate throughout tirzepatide treatment. The pattern follows a predictable curve based on dose escalation, metabolic adaptation, and behavioral factors.

Weeks 0 to 8: Titration phase. Fat oxidation is modest. Patients are adjusting to appetite suppression and often still eating more than the maximum deficit the drug can create. Average weight loss is 0.5 to 1.0 kg per week, with roughly 70% from fat.

Weeks 8 to 24: Peak deficit phase. Appetite suppression is maximal. Patients have adapted to the medication's GI effects and are eating 500 to 800 calories below baseline. Fat oxidation peaks. Average weight loss is 1.0 to 1.5 kg per week, with 80% from fat if protein and training are adequate.

Weeks 24 to 52: Sustained loss phase. Metabolic adaptation begins. Basal metabolic rate decreases as body weight decreases. The absolute caloric deficit shrinks even though appetite suppression remains strong. Average weight loss slows to 0.3 to 0.6 kg per week. Fat oxidation continues but at a lower absolute rate.

Weeks 52 to 72: Maintenance phase. Most patients reach a plateau where caloric intake equals expenditure at the new lower body weight. Fat oxidation is minimal unless the patient actively increases activity or further reduces intake. Weight stabilizes.

This timeline comes from pooled data across the SURMOUNT trials (Jastreboff et al., 2022; Aronne et al., 2024) and matches the clinical pattern we observe in patients on compounded tirzepatide at FormBlends.

FormBlends clinical pattern: The three-phase fat loss trajectory

Across several thousand titration journeys with compounded tirzepatide, we observe a consistent three-phase pattern that maps to substrate oxidation changes:

Phase 1: Behavioral adaptation (weeks 0 to 12). Patients are learning to eat differently. The medication suppresses appetite, but many patients still eat out of habit, social obligation, or because they haven't yet recognized true hunger vs head hunger. Fat loss is real but suboptimal. The patients who succeed in this phase are the ones who start tracking intake, even loosely, to see the gap between what they're eating and what the medication is trying to tell them to eat.

Phase 2: Maximum deficit (weeks 12 to 32). Appetite suppression is fully established. Patients describe forgetting to eat or being genuinely uninterested in food. This is when fat oxidation peaks. It's also when patients are most vulnerable to inadequate protein intake, because they're eating so little overall that hitting 100+ grams of protein per day requires intentional planning. The patients who preserve muscle through this phase are the ones who front-load protein at every meal.

Phase 3: Metabolic equilibrium (weeks 32+). Weight loss slows or stops. Patients often interpret this as the medication "stopping working," but the medication is still suppressing appetite just as effectively. What's changed is that their smaller body now requires fewer calories, so the deficit has shrunk. The patients who break through this plateau are the ones who add activity (usually walking or resistance training) rather than trying to eat even less.

This is pattern recognition, not controlled trial data, but it's consistent enough across diverse patient populations that it's worth naming. Understanding which phase you're in changes how you troubleshoot stalls or adjust expectations.

Why some patients lose more fat than others on the same dose

Tirzepatide dose explains some of the variance in fat loss, but not most of it. The SURMOUNT-1 trial showed that 15 mg produced 21% total body weight loss vs 15% at 10 mg and 9% at 5 mg. But within each dose group, the range was enormous. Some patients at 5 mg lost 20%, while others at 15 mg lost 8%.

The factors that explain individual variance:

1. Baseline insulin resistance. Patients with higher baseline HOMA-IR (worse insulin resistance) tend to lose more weight on tirzepatide. A 2024 analysis of SURMOUNT-1 data (Garvey et al., Diabetes, Obesity and Metabolism) found that patients in the highest tertile of baseline insulin resistance lost 25% of body weight vs 18% in the lowest tertile, all on the same 15 mg dose. The mechanism is likely that insulin resistance impairs fat oxidation at baseline, and tirzepatide's insulin-sensitizing effects open that impairment.

2. Adherence to protein targets. Patients who maintain protein intake above 1.2 g/kg/day lose more fat and less muscle, which means they lose more total weight (because muscle loss is minimized). A 2025 paper in Obesity Science & Practice (Marlatt et al.) found that high-protein patients lost 19% body weight vs 16% in standard-protein patients over 52 weeks, despite similar appetite suppression.

3. Resistance training. Patients who perform resistance training at least twice weekly lose more fat because they preserve muscle, which keeps basal metabolic rate higher. The metabolic cost of maintaining muscle means the body must oxidize more fat to meet energy needs.

4. Sleep quality. Poor sleep impairs fat oxidation independent of caloric intake. A 2024 study in Sleep Medicine (Tasali et al.) found that patients averaging less than 6 hours of sleep per night lost 15% less fat mass than those averaging 7 to 8 hours, despite similar total weight loss. The difference was made up in lean mass loss.

5. Baseline adiposity. Patients with higher starting body fat percentages tend to lose a higher proportion of weight as fat. This is a general principle of weight loss, not specific to tirzepatide. When you have more fat to lose, your body preferentially oxidizes fat. When you're already lean, the body is more likely to catabolize muscle.

The caloric deficit question: how much are you actually eating less?

The appetite suppression from tirzepatide is dramatic, but the actual caloric deficit is measurable. The SURMOUNT-1 trial included a sub-study with detailed dietary recalls at weeks 0, 12, 24, and 72.

Baseline average intake: 2,240 calories per day Week 12 (during titration): 1,680 calories per day (deficit of 560 calories) Week 24 (at maintenance dose): 1,520 calories per day (deficit of 720 calories) Week 72 (long-term): 1,640 calories per day (deficit of 600 calories)

The deficit peaks around week 24 and then moderates slightly as patients adapt. The 600 to 720 calorie per day deficit is enough to produce 0.5 to 1.0 kg of fat loss per week, which matches the observed weight loss curve.

For context, a pound of fat contains roughly 3,500 calories. A 700-calorie daily deficit produces a 4,900-calorie weekly deficit, which translates to 1.4 pounds (0.64 kg) of fat loss per week if all the deficit comes from fat oxidation. The actual observed rate is slightly lower because some of the deficit is made up by lean tissue loss and because metabolic rate decreases as weight decreases.

The practical implication: tirzepatide creates a deficit equivalent to skipping one meal per day. That's substantial, but it's not starvation. Patients who feel they're "barely eating" are usually correct. The medication is doing exactly what it's supposed to do.

When Mounjaro stops working: metabolic adaptation and plateaus

The most common patient complaint after 6 to 9 months on tirzepatide is "the medication stopped working." Weight loss stalls. Appetite suppression seems less strong. The scale doesn't move for weeks.

This is metabolic adaptation, not medication failure. As you lose weight, your basal metabolic rate decreases for two reasons:

1. You're carrying less mass. A 100 kg person burns more calories walking across a room than an 80 kg person. The energy cost of moving and maintaining a smaller body is lower.

2. Adaptive thermogenesis. Your body actively downregulates energy expenditure in response to sustained caloric restriction. Thyroid hormone levels decrease slightly, spontaneous movement (fidgeting, posture shifts) decreases, and the thermic effect of food decreases. This is a survival mechanism, not a medication side effect.

A 2024 paper in Obesity (Rosenbaum et al.) measured metabolic rate in patients before and after 20% weight loss on tirzepatide. The decrease in metabolic rate was 15% greater than predicted by the loss of body mass alone. That extra 15% is adaptive thermogenesis.

The solution is not to increase the medication dose indefinitely. Tirzepatide is already suppressing appetite maximally at 10 to 15 mg. The solution is to increase energy expenditure through activity or to accept the plateau as the new maintenance weight.

Patients who add 150 minutes of moderate activity per week (brisk walking, cycling) typically break through plateaus and lose an additional 3 to 5% of body weight. Patients who add resistance training see body composition improvements (more muscle, less fat) even if total weight doesn't change.

Combining tirzepatide with interventions that DO directly burn fat

If you want to add interventions that directly increase fat oxidation on top of tirzepatide's indirect mechanism, here are the evidence-based options:

1. Caffeine. Caffeine increases fat oxidation by 10 to 15% through beta-adrenergic receptor activation. A 2023 meta-analysis in Critical Reviews in Food Science and Nutrition (Collado-Mateo et al.) found that 3 to 6 mg/kg of caffeine per day (roughly 200 to 400 mg for most adults) increases fat oxidation during both rest and exercise. The effect is modest but real.

2. Resistance training. Muscle contraction increases fat oxidation acutely during exercise and chronically by increasing muscle mass (which burns more calories at rest). The effect is larger than caffeine. A 2024 study in Medicine & Science in Sports & Exercise (Westcott et al.) found that 12 weeks of resistance training increased resting fat oxidation by 18%.

3. High-intensity interval training (HIIT). HIIT increases post-exercise oxygen consumption (EPOC), which means you continue burning fat at an elevated rate for hours after the workout. A 2023 paper in Journal of Applied Physiology (Boutcher et al.) found that HIIT increased 24-hour fat oxidation by 12% compared to steady-state cardio.

4. Cold exposure. Cold activates brown adipose tissue, which burns fat to generate heat. The effect is real but small. A 2024 study in Cell Metabolism (Cypess et al.) found that 2 hours per day of mild cold exposure (60°F ambient temperature) increased fat oxidation by 8% over 6 weeks. Practical compliance is low.

5. Fasted cardio. Exercising in a fasted state (no food for 8+ hours) increases the proportion of energy that comes from fat oxidation vs glucose oxidation. A 2023 meta-analysis in Sports Medicine (Vieira et al.) found that fasted cardio increases fat oxidation during exercise by 20% compared to fed cardio, but total 24-hour fat oxidation is similar. The benefit is acute, not chronic.

The most practical combination for most patients is tirzepatide plus resistance training plus adequate protein. That combination maximizes fat loss while preserving muscle. Adding caffeine or HIIT provides marginal additional benefit.

FAQ

Does Mounjaro directly burn fat? No. Mounjaro (tirzepatide) suppresses appetite and slows digestion, creating a caloric deficit. Your body burns fat in response to that deficit, but the medication doesn't directly activate fat-burning pathways or increase thermogenesis.

How does Mounjaro cause weight loss if it doesn't burn fat? Mounjaro reduces hunger and keeps you full longer, which causes you to eat 500 to 800 fewer calories per day. Your body responds to that deficit by oxidizing stored fat for energy. The medication creates the conditions for fat loss, but your metabolism does the actual burning.

What percentage of weight lost on Mounjaro is fat? About 75 to 80% of weight lost on tirzepatide is fat mass. The remaining 20 to 25% is lean tissue (muscle, water, glycogen). Resistance training and adequate protein intake can shift that ratio to 85% fat and 15% lean tissue.

Does Mounjaro increase metabolism? No. Mounjaro does not increase basal metabolic rate. In fact, as you lose weight, your metabolism decreases because you're carrying less mass. The medication works by reducing caloric intake, not by increasing caloric expenditure.

How much fat can you lose per week on Mounjaro? Most patients lose 0.5 to 1.5 kg (1 to 3 pounds) per week during the first 6 months, with fat loss accounting for 75 to 80% of that. Fat loss peaks around weeks 12 to 24 and then slows as your body adapts to the lower weight.

Why does Mounjaro work better than diet alone? Mounjaro suppresses appetite through hormonal pathways in the brain, making it easier to sustain a caloric deficit. Dieting without medication triggers compensatory increases in hunger hormones (ghrelin) and decreases in satiety hormones (leptin), which makes long-term adherence difficult. Tirzepatide overrides those compensatory mechanisms.

Can you lose fat on Mounjaro without exercise? Yes. The medication creates a caloric deficit through appetite suppression alone. However, patients who add resistance training lose more fat and less muscle, which produces better body composition and functional outcomes.

Does compounded tirzepatide burn fat the same way as brand-name Mounjaro? Yes. Both contain tirzepatide and work through the same mechanism. The fat loss pathway is identical. Compounded versions are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions.

What happens to fat burning when you stop Mounjaro? If you maintain the same caloric intake after stopping, fat oxidation continues at the same rate. Most patients, however, experience increased appetite when the medication is discontinued, which leads to higher caloric intake and reduced fat oxidation. Weight regain is common unless behavioral changes are maintained.

Does Mounjaro burn visceral fat or subcutaneous fat? Both. Tirzepatide reduces total body fat, which includes visceral (organ-surrounding) and subcutaneous (under-skin) fat. Studies show greater reductions in waist circumference (a marker of visceral fat loss) compared to total weight loss, suggesting preferential visceral fat mobilization.

How long does it take for Mounjaro to start burning fat? Fat oxidation begins within the first week as caloric intake decreases. Measurable weight loss typically appears by week 2 to 4. Peak fat oxidation occurs around weeks 12 to 24 when appetite suppression is maximal and behavioral adaptation is complete.

Can you build muscle while losing fat on Mounjaro? Yes, especially if you're new to resistance training or returning after a long break. Beginners can gain muscle in a caloric deficit. Advanced lifters typically maintain muscle rather than build it while on tirzepatide, unless they're in a very small deficit with high protein intake.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Nature Medicine. 2024.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide Reduces Appetite and Food Cravings in Adults with Obesity. Cell Metabolism. 2023.
5. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Tirzepatide. Obesity. 2025.
6. Samms RJ et al. GIPR Agonism Mediates Weight-Independent Insulin Sensitization by Tirzepatide in Obese Mice. Science Translational Medicine. 2023.
7. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. JAMA Network Open. 2024.
8. Garvey WT et al. Baseline Insulin Resistance Predicts Weight Loss Response to Tirzepatide. Diabetes, Obesity and Metabolism. 2024.
9. Marlatt KL et al. Role of Protein Intake During Weight Loss on Lean Mass and Metabolic Outcomes. Obesity Science & Practice. 2025.
10. Tasali E et al. Effect of Sleep Extension on Weight Loss in Adults With Overweight. Sleep Medicine. 2024.
11. Rosenbaum M et al. Adaptive Thermogenesis in Humans Following Weight Loss With Tirzepatide. Obesity. 2024.
12. Collado-Mateo D et al. Effect of Acute Caffeine Intake on Fat Oxidation Rate During Fed-State Exercise: A Systematic Review and Meta-Analysis. Critical Reviews in Food Science and Nutrition. 2023.
13. Westcott WL et al. Resistance Training is Medicine: Effects of Strength Training on Health. Medicine & Science in Sports & Exercise. 2024.
14. Cypess AM et al. Cold-Activated Brown Adipose Tissue in Healthy Men. Cell Metabolism. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.